AbbVie Sets $80 Monthly Price for Its Vuity Eye Drug

AbbVie has priced its new drug for age-related blurry near-vision, Vuity, at around $80 for a 30-day supply.

The drug, which in October became the first FDA-approved eye drop to treat the extremely common eye condition, is now available by prescription as an alternative to reading glasses, contact lenses or laser eye surgery.

Vuity (pilocarpine HCl ophthalmic solution) is delivered using the company’s pHast technology, which enables the therapy to adjust to the pH of the eye’s tear film. The drug works by shrinking the pupil to improve near-vision.

The condition, formally known as presbyopia, affects approximately 128 million Americans.